Diagnostic test developer Talis Biomedical Corp. and certain officers and directors were hit with a securities class action Friday in California Northern District Court over the company’s Feb. 2021 IPO. The court action, filed by Glancy Prongay & Murray and the Law Offices of Frank R. Cruz, accuses the defendants of concealing likely delays in the launch of a COVID-19 test. The suit also names JPMorgan, BofA Securities, Piper Sandler and BTIG in their roles as underwriters of the IPO. Counsel have not yet appeared for the defendants. The case is 3:22-cv-00105, Modrak v. Talis Biomedical Corporation et al.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]